A note on the catch-up time method for estimating lead or sojourn time in prostate cancer screening
- PMID: 23364954
- PMCID: PMC3752966
- DOI: 10.1002/sim.5750
A note on the catch-up time method for estimating lead or sojourn time in prostate cancer screening
Abstract
Models of cancer screening assume that cancers are detectable by screening before being diagnosed clinically through symptoms. The duration of this preclinical phase is called sojourn time, and it determines how much diagnosis might be advanced in time by the screening test (lead time). In the catch-up time method, mean sojourn time or lead time are estimated as the time needed for cumulative incidence in an unscreened population to catch up with the detection rate (prevalence) at a first screening test. The method has been proposed as a substitute of the prevalence/incidence ratio in the case of prostate cancer where incidence cannot be treated as a constant. A model is proposed to justify this estimator. It is shown that this model is different from classic Markov-type models developed for breast cancer screening. In both models, the catch-up time method results in biased estimates of mean sojourn time.
Keywords: cancer screening; lead time; prostate cancer; sojourn time.
Copyright © 2013 John Wiley & Sons, Ltd.
Figures



Similar articles
-
A multistate survival model of the natural history of cancer using data from screened and unscreened population.Stat Med. 2021 Jul 20;40(16):3791-3807. doi: 10.1002/sim.8998. Epub 2021 May 5. Stat Med. 2021. PMID: 33951215
-
Conditions for Valid Empirical Estimates of Cancer Overdiagnosis in Randomized Trials and Population Studies.Am J Epidemiol. 2016 Jul 15;184(2):140-7. doi: 10.1093/aje/kwv342. Epub 2016 Jun 29. Am J Epidemiol. 2016. PMID: 27358266 Free PMC article.
-
Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.J Natl Cancer Inst. 2009 Mar 18;101(6):374-83. doi: 10.1093/jnci/djp001. Epub 2009 Mar 10. J Natl Cancer Inst. 2009. PMID: 19276453 Free PMC article.
-
Smarter screening for prostate cancer.World J Urol. 2019 Jun;37(6):991-999. doi: 10.1007/s00345-019-02719-5. Epub 2019 Mar 11. World J Urol. 2019. PMID: 30859272 Review.
-
Prevention of Prostate Cancer Morbidity and Mortality: Primary Prevention and Early Detection.Med Clin North Am. 2017 Jul;101(4):787-806. doi: 10.1016/j.mcna.2017.03.009. Med Clin North Am. 2017. PMID: 28577627 Review.
Cited by
-
Optimal Interval for Repeated Gastric Cancer Screening in Normal-Risk Healthy Korean Adults: A Retrospective Cohort Study.Cancer Res Treat. 2015 Oct;47(4):564-8. doi: 10.4143/crt.2014.098. Epub 2015 Jan 30. Cancer Res Treat. 2015. PMID: 25687874 Free PMC article.
-
Overdiagnosis and overtreatment of prostate cancer.Eur Urol. 2014 Jun;65(6):1046-55. doi: 10.1016/j.eururo.2013.12.062. Epub 2014 Jan 9. Eur Urol. 2014. PMID: 24439788 Free PMC article. Review.
-
Mean sojourn time of preclinical gastric cancer in Korean men: a retrospective observational study.J Prev Med Public Health. 2014 Jul;47(4):201-5. doi: 10.3961/jpmph.2014.47.4.201. Epub 2014 Jul 31. J Prev Med Public Health. 2014. PMID: 25139166 Free PMC article.
-
Baseline and annual repeat rounds of screening: implications for optimal regimens of screening.Eur Radiol. 2018 Mar;28(3):1085-1094. doi: 10.1007/s00330-017-5029-z. Epub 2017 Oct 5. Eur Radiol. 2018. PMID: 28983713
-
Methodological issues for determining intervals of subsequent cancer screening.Epidemiol Health. 2014 Jul 30;36:e2014010. doi: 10.4178/epih/e2014010. eCollection 2014. Epidemiol Health. 2014. PMID: 25078383 Free PMC article.
References
-
- Zelen M, Feinleib M. On the theory of screening for chronic diseases. Biometrika. 1969;56:601–614.
-
- Day N, Walter S. Simplified models of screening for chronic disease: estimation procedures from mass screening programmes. Biometrics. 1984;40(1):1–14. PMID: 6733223. - PubMed
-
- Auvinen A, Määttänen L, Stenman U, Tammela T, Rannikko S, Aro J, Juusela H, Hakama M. Lead-time in prostate cancer screening (Finland) Cancer Causes Control. 2002;13(3):279–285. PMID: 12020110. - PubMed
-
- Finne P, Fallah M, Hakama M, Ciatto S, Hugosson J, de Koning H, Moss S, Nelen V, Auvinen A. Lead-time in the European Randomised Study of Screening for Prostate Cancer. European Journal of Cancer. 2010;46(17):3102–3108. PMID: 21047593. - PubMed
-
- Pashayan N, Duffy S, Pharoah P, Greenberg D, Donovan J, Martin R, Hamdy F, Neal D. Mean sojourn time, overdiagnosis and reduction in advances stage prostate cancer due to screening with PSA: implication of sojourn time on screening. British Journal of Cancer. 2009;100(7):1198–1204. PMID:19293796. - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical